Roche Holding's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 0.02% per year. Roche Holding's return on equity is 35%, and it has net margins of 17.5%.
How Roche Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
SWX:ROG Revenue, expenses and earnings (CHF Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 24
60,581
10,619
13,346
13,381
31 Mar 24
60,511
11,059
13,416
13,463
31 Dec 23
60,441
11,498
13,486
13,545
30 Sep 23
61,486
11,263
13,738
13,669
30 Jun 23
62,530
11,028
13,894
13,793
31 Mar 23
64,172
11,725
13,793
13,696
31 Dec 22
65,814
12,421
13,691
13,599
30 Sep 22
66,716
13,539
13,262
13,592
30 Jun 22
67,617
14,657
12,833
13,585
31 Mar 22
66,734
14,294
12,405
13,804
31 Dec 21
65,850
13,930
11,977
14,022
30 Sep 21
63,974
13,975
12,037
13,747
30 Jun 21
62,098
14,019
12,097
13,472
31 Mar 21
61,221
14,157
12,026
13,019
31 Dec 20
60,343
14,295
11,954
12,566
30 Sep 20
61,361
13,626
12,289
12,382
30 Jun 20
62,378
12,957
12,624
12,198
31 Mar 20
63,065
13,227
12,904
12,061
31 Dec 19
63,751
13,497
13,183
11,923
30 Sep 19
62,736
12,654
13,275
11,702
30 Jun 19
61,721
11,810
12,933
11,480
31 Mar 19
60,609
11,155
12,800
11,337
31 Dec 18
59,497
10,500
12,667
11,194
30 Sep 18
58,611
10,483
12,641
11,005
30 Jun 18
57,725
10,465
12,615
10,815
31 Mar 18
56,736
9,549
12,322
10,672
31 Dec 17
55,746
8,633
12,029
10,529
30 Sep 17
54,961
9,154
11,148
10,411
30 Jun 17
54,176
9,675
10,266
10,293
31 Mar 17
53,406
9,626
10,305
10,172
31 Dec 16
52,636
9,576
10,343
10,050
30 Sep 16
52,109
9,332
10,655
9,975
30 Jun 16
51,581
9,087
10,966
9,900
31 Mar 16
50,992
8,975
10,953
9,678
31 Dec 15
50,403
8,863
10,940
9,455
30 Sep 15
50,364
8,908
10,978
9,305
30 Jun 15
50,324
8,953
11,004
9,155
31 Mar 15
50,095
9,143
10,924
9,068
31 Dec 14
49,866
9,332
10,844
8,980
30 Sep 14
49,300
10,044
10,698
8,899
30 Jun 14
48,733
10,756
10,551
8,817
31 Mar 14
48,673
10,960
10,569
8,787
31 Dec 13
48,612
11,164
10,587
8,756
Quality Earnings: ROG has a large one-off loss of CHF3.8B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: ROG's current net profit margins (17.5%) are lower than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ROG's earnings have declined by 3.4% per year over the past 5 years.
Accelerating Growth: ROG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ROG had negative earnings growth (-3.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.2%).
Return on Equity
High ROE: Whilst ROG's Return on Equity (34.96%) is high, this metric is skewed due to their high level of debt.
